Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,411 across all filing types
Latest filing 2024-03-19 Capital/Financing Update
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
F-3ASR
Capital/Financing Update Classification · 100% confidence The document is a Form F-3 Registration Statement filed with the SEC, which is a registration statement under the Securities Act of 1933. It is a prospectus for debt securities offered by AstraZeneca PLC and its subsidiary AstraZeneca Finance LLC. The document includes detailed information about the securities, risk factors, company background, and legal matters. It is not an annual report, earnings release, or any other financial report but a capital markets filing related to securities issuance. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), indicating it is the full registration statement, not just an announcement or a brief notice.
2024-03-19 English
FORM 6-K
M&A Activity Classification · 95% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content primarily announces AstraZeneca's definitive agreement to acquire Fusion Pharmaceuticals Inc., detailing the transaction terms, strategic rationale, and forward-looking statements. It includes financial considerations and references to future proxy filings related to the acquisition. The document is not a full annual or quarterly report, audit report, earnings release, or management discussion. It is an announcement of a significant merger and acquisition activity. Therefore, the document fits best under the category of M&A Activity (TAR), which covers announcements and documents related to merger proposals or takeover bids. The document length (15,000 characters) and detailed content confirm it is not merely a brief announcement or proxy solicitation but a substantive M&A announcement.
2024-03-19 English
AstraZeneca to acquire Fusion
M&A Activity Classification · 99% confidence The document is a formal announcement released via RNS (RNS Number: 3850H) on March 19, 2024, detailing AstraZeneca's definitive agreement to acquire Fusion Pharmaceuticals. The content focuses on a major corporate transaction (M&A), including financial considerations, regulatory milestones, and the strategic rationale. This type of announcement, which is a material event disclosure made through a regulatory news service, fits best under the general 'Regulatory Filings' category (RNS) as it is not a specific report like 10-K, ER, or IR, nor is it a proxy statement (DEF 14A/PSI) or a management discussion (MDA). While it relates to M&A (TAR), RNS is often used for the initial, broad regulatory disclosure of such events via the LSE mechanism mentioned at the end ('This information is provided by RNS...'). Given the context of being a broad regulatory news service release about a significant event, RNS is the most appropriate general classification, although TAR is a close secondary fit if the focus is purely on the M&A nature.
2024-03-19 English
ASTRAZENECA TO ACQUIRE AMOLYT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filing by AstraZeneca PLC, which is a report of a foreign issuer pursuant to the Securities Exchange Act of 1934. The content primarily announces AstraZeneca's definitive agreement to acquire Amolyt Pharma, detailing the acquisition terms, strategic rationale, and forward-looking statements. There are no financial statements or detailed financial performance data included. The document is an announcement of a corporate transaction (acquisition) rather than a full merger filing or tender offer document. It is not a full annual or interim report, nor is it a call transcript or governance document. Given the nature of the content—an acquisition announcement by a foreign issuer in a Form 6-K—the most appropriate classification is a Regulatory Filing (RNS), which serves as a fallback for miscellaneous regulatory announcements that do not fit other categories. The document length (over 13,000 characters) and detailed content support this classification with high confidence.
2024-03-14 English
AstraZeneca to acquire Amolyt
M&A Activity Classification · 99% confidence The document is a formal announcement disseminated via RNS (RNS Number : 8414G) on March 14, 2024, detailing AstraZeneca's definitive agreement to acquire Amolyt Pharma for up to $1.05 billion. This announcement concerns a significant corporate transaction (M&A activity) and includes financial considerations and closing timelines. While it is distributed through the RNS system, the core subject matter is a merger/acquisition proposal, which aligns best with the 'M&A Activity' category (TAR). It is not a general regulatory filing (RNS) or a report publication announcement (RPA) because it contains the substantive details of the transaction itself, not just a notice that a report is available. It is also not a financing update (CAP) as it is an acquisition, not fundraising.
2024-03-14 English
DIRECTOR/PDMR SHAREHOLDING
Director's Dealing Classification · 100% confidence The document is a Form 6-K filed with the SEC by AstraZeneca PLC, reporting a transaction by a Person Discharging Managerial Responsibilities (PDMR), specifically the vesting of shares to the CEO under a performance share plan. The content focuses on insider shareholding changes and compliance with EU Market Abuse Regulation. There are no financial statements, earnings data, or management discussion of results. The document is a regulatory filing reporting insider transactions, which fits the definition of Director's Dealing (DIRS). The document length is about 5292 characters, sufficient to contain detailed transaction information. Therefore, the classification is DIRS with high confidence.
2024-03-12 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.